Sorrento reports early-stage resiniferatoxin data in osteoarthritis-related knee pain; shares up 7%

• Sorrento (SRNE +7.3%) reports positive results from a Phase 1b clinical trial evaluating resiniferatoxin (RTX) in patients with moderate-to-severe pain due to osteoarthritis of the knee.
• 98.8% (n=83/84) of patients experienced a treatment-emergent adverse event (TEAE) but only 6% (n=5/84) were severe. Most were mild-to-moderate post-procedural pain. All resolved in less than a day.
• At day 84, the average reduction from baseline in WOMAC A1 score (measure of pain from walking on a flat surface), was 4.9 points compared to 2.6 points for placebo for the 12.5 ug dose (the dose to be tested in subsequent trials). In patients qualifying for total knee replacement, 68% improved by at least 20% versus 20% in the control arm.
• Phase 2 & 3 studies are next up.